

European Congress of Cytopathology 2023


FNA ROSE case presentations

Leonie Wheeldon


Consultant Biomedical Scientist diagnostic cytopathology Executive for the British Association for Cytopathology

Diagnostic Cytopathology Royal Cornwall Hospital UK

BMS led ROSE service Head and neck, Thyroid, Lung/EBUS, EUS Remote ROSE for head and neck











Female 78 years Low grade B cell follicular lymphoma since 2013 Sept 2022 - EUS pancreatic lesion – B cell follicular lymphoma









Treated with R-CVP (Chemoimmunotherapy and steroids) Good result after 3 cycles but progression after 6 cycles Growth of known pancreatic lesion, multiple hepatic metastases throughout the liver and pulmonary mass enlargement.

> MDT discussion – Treat as high grade transformation or obtain further sampling / route to sampling?

Pulmonary mass was biopsied – organising pneumonia


BMT - No evidence of lymphomatous involvement

Sample liver lesions




Liver sampled via EUS with ROSE

X 2 passes – Technically challenging to sample – ROSE insufficient sampling








New needles – flushed with saline to prevent damage and fragmentation Straight into formalin – no shrinkage from alcohol

Went straight for 19G No need for ROSE- reduce number of passes into the pancreas




Sometimes the decision night be not to ROSE

Pancreas 19G









The morphological and immunoprofile are in keeping with the already known lymphoproliferative disorder. There is extensive necrosis in the sample which is likely to represent response to treatment.




Despite being insufficient on ROSE we still routinely make a cell block from the residual material





Human Liver Photograph by Pixologicstudio - Fine Art America







Liver Cell block

Fatty liver disease No malignant cells Hepatocytes No significant lymphoid population

















Patient had a very early-stage Melanoma excised - left eyebrow in March 2022. Declined WLE







There is no evidence of metastatic melanoma in the pancreatic sample



EUS Pancreas: Follicular lymphoma with extensive necrosis suggestive of treatment response

EUS Liver: Metastatic melanoma - BRAF testing - Negative

For Pembrolizumab immunotherapy Intent: Disease response and control

Sadly, the patient passed away in July 2023



Key points

Full information regarding history and previous sampling is essential prior to ROSE

Use larger needles for lymphoid populations

Process all the residual material even if the sample is non-diagnostic or only contains a few cells at ROSE

Change of contaminated consumables between sites


Accuracy of sample labelling




Female 69 years

Complex history. pT2pN1a Triple negative breast Cancer – 2009 treated by surgery, adjuvant chemotherapy and adjuvant RT Low grade Follicular lymphoma – Axilla 2014 treated with Rituximab / Bendamustine – Remission 2017









2022 - EBUS T3 N3 lung adenocarcinoma. EGFRm - / ALK - / Ros1 - / PDL1 0% / KRAS wild Carboplatin-Pemetrexed-Pembrolizumab Chemoimmunotherapy




CT: Multiple abdominal nodes. ? Lymphoma - clinically

2 different disease processes? – Lung, Lymphoma, Breast carcinoma EUS peri gastric node









EUS peri gastric node - Pass 1 with ROSE. Pass 2 and 3 straight into formalin








Peri gastric node - 19G cell block








Negative - GATA3, SOX10, CK20, CD56 and synaptophysin


Ki67 expression is seen in 100% of the tumour cells.


Positive staining for MOC31














tish Association Cytopathology

Reviewed the previous EBUS sample - poorly-differentiated, TTF1 + lung adenocarcinoma

Small fragments showed aberrant CD45 expression







<u>J Clin Pathol.</u> 2007 Aug; 60(8): 936–938. doi: <u>10.1136/jcp.2006.044750</u> PMCID: PMC1994499 PMID: <u>17660336</u>

Leucocyte common antigen (CD45) and CD5 positivity in an "undifferentiated" carcinoma: a potential diagnostic pitfall

Nyethane Ngo, Kaushik Patel, Peter G Isaacson, and Kikkeri N Naresh

Author information
Article notes
Copyright and License information
<u>PMC Disclaimer</u>



Co-expression of CD45 and cytokeratin markers is rare. In this case, however, negative staining for PAX5, CD3, CD10, CD3 and CD79a, together with positive staining for TTF1 and cytokeratin markers are more likely to represent metastasis from a lung primary carcinoma. The CD45 expression is again regarded as aberrant rather than indicative of a lymphoproliferative disorder. Negative staining for GATA3 and SOX10 makes metastatic breast carcinoma unlikely.

Clinical and radiological correlation is essential - MDT

Next generation sequencing – no fusions or driver mutations detected Treated with Carboplatin-Pemetrexed – Initial response but progressed Best supportive care



Full information regarding history and previous sampling is essential prior to ROSE

Algorithms to aid actions at ROSE – need to know what to do if its outside the scope of the algorithm

Use larger needles for lymphoid / dissociated single cell populations

Shared learning

DON'T PANIC!



Thank you for your time



